New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 1, 2012
16:58 EDTPBY, IDTI, PFE, HLF, PLXT, CHK, PFCB, SHLDOn The Fly: Closing Wrap
Stocks on Wall Street were higher following an encouraging report on U.S. manufacturing. Stock futures were quiet during the pre-market trading session as investors digested the latest round of corporate earnings without having to deal with any new economic reports. The futures action led to a relatively quiet open for the broader market. The market received a lift following the ISM manufacturing report, which was better than expected. The data lifted to the market to fresh recovery highs on the Dow while recent highs were also within striking distance for the Nasdaq and S&P. The market met resistance at the new levels and pared its gains in the afternoon hours... ECONOMIC EVENTS: Domestically, the ISM manufacturing index rose to 54.8 in April, beating forecasts for a reading of 53.0. Construction spending for March increased by 0.1%, versus expectations of an increase of 0.5%. In China, the official purchasing managersí index for manufacturing rose to 53.3 in April... COMPANY NEWS: Chesapeake (CHK) said it would appoint a new non-executive chairman in the near future to replace CEO Aubrey McClendon in that role. McClendon, who will remain on as CEO, also agreed to an early termination of the well participation program that has drawn a firestorm of recent backlash from media, investors and regulators. Shares gained $1.16, or 6.29%, to close at $19.60 ahead of the company's earnings report, due out after the bell... Dow component Pfizer (PFE) reported earnings that beat consensus but lowered its full year forecast to account for the divestiture of its Nutrition business... Sears Holdings (SHLD) gained $8.27, or 15.38%, to $62.05 after saying its Q1 domestic same store sales fell 1.3%, which was a significant improvement from the declines seen in the same period last year, and forecasting a return to earnings from continuing operations in the quarter... MAJOR MOVERS: Among the notable gainers were PLX Technology (PLXT), up $2.68, or 67.34%, to $6.66, after saying it will be acquired by Integrated Device Technology (IDTI) for $7 per share in cash and stock, and P.F. Chang's (PFCB), up $11.79, or 29.71%, to $51.48, on news it will be acquired and taken private by Centerbridge Partners for $51.50 per share in cash. Noteworthy losers included Herbalife (HLF), down $14.02, or 19.94%, to $56.30, after hedge fund manager and noted short-seller David Einhorn asked some critical questions during the company's earnings conference call, and Pep Boys (PBY), down $3.31, or 22.17%, to $11.62, after the Gores Group hinted it may attempt to walk away from its proposed $1B takeover of the company following Pep Boys' warning on its Q1 results... INDICES: The Dow gained 65.69, or 0.50%, to 13,279.32; the Nasdaq rose 4.08, or 0.13%, to 3,050.44; and the S&P 500 added 7.91, or 0.57%, to 1,405.82.
News For CHK;PFE;SHLD;PLXT;IDTI;PFCB;HLF;PBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
February 2, 2016
06:52 EDTPFEPfizer sees FY16 adjusted EPS $2.20-$2.30, consensus $2.36
Sees FY16 revenue $49B-$51B, consensus $52.49B. Expects impact of January 2016 FX rates compared to 2015 FX rates to negatively impact adjusted EPS by 9c and revenue by $1.5B. Expects currency impact related to Venezuela to negatively impact EPS by 7c and revenue by $800M. Sees FY16 effective tax rate of approximately 24%. Sees FY16 adjusted R&D expenses $7.3B-$7.8B and adjusted SI&A expenses of $13.2B-$14.2B.
06:49 EDTPFEPfizer reports Q4 Innovative Products revenue $7.64B
Subscribe for More Information
06:47 EDTPFEPfizer reports Q4 adjusted EPS 53c, consensus 52c
Reports Q4 revenue $14.05B, consensus $13.56B.
06:44 EDTIDTIIntegrated Device downgraded to Neutral from Buy at BofA/Merrill
February 1, 2016
19:09 EDTIDTIOn The Fly: After Hours Movers
UP AFTER EARNINGS: Alphabet (GOOG, GOOGL), up 5.2% and 4.7%, respectively... Mattel (MAT), up 5.6%... Anadarko Petroleum (APC), up 4%... AFLAC (AFL), up 1.5%. ALSO HIGHER: PVH Corp. (PVH), up 8.1% after giving guidance for fiscal 2015 and entering a license agreement with G-III Apparel (GIII) for Tommy Hilfiger womenswear collections. DOWN AFTER EARNINGS: Integrated Device (IDTI), down 15.8%... Rent-A-Center (RCII), down 9.6%. ALSO LOWER: Pixelworks (PXLW), down 5.7% after giving fourth quarter guidance and announcing the resignation of its CEO... PDL BioPharma (PDLI), down 14.3% after cutting its quarterly dividend to 5c per share from 15c per share.
16:09 EDTIDTIIntegrated Device expects 'meaningful' accretion from ZMDI acquisition
Subscribe for More Information
16:07 EDTIDTIIntegrated Device reports Q3 adjusted EPS 35c, consensus 35c
Subscribe for More Information
16:01 EDTPFE, CHKOptions Update; February 1, 2016
Subscribe for More Information
14:32 EDTPFENotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Exxon Mobil (XOM), consensus 64c... Pfizer (PFE), consensus 52c... United Parcel Service (UPS), consensus $1.42... Dow Chemical (DOW), consensus 70c... Emerson Electric (EMR), consensus 51c... Archer-Daniels-Midland (ADM), consensus 66c... Baxter (BAX), consensus 32c... Sirius XM (SIRI), consensus 3c... Royal Caribbean Cruises (RCL), consensus 92c... Ally Financial (ALLY), consensus 51c... Michael Kors (KORS), consensus $1.46... ADT Corp. (ADT), consensus 46c.
14:32 EDTIDTINotable companies reporting after market close
Subscribe for More Information
13:25 EDTPFEEarnings Watch: Pfizer shares down approximately 12% since last earnings report
Pfizer (PFE) is scheduled to report fourth quarter earnings before the market open on Tuesday, February 2, with a conference call scheduled for 10:00 am ET. Pfizer, a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. EXPECTATIONS: Analysts are looking for earnings per share of 52c on revenue of $13.57B, according to First Call. The consensus range for EPS is 49c-54c on revenue of $13.08B-$13.99B. LAST QUARTER: After completing its Hospira acquisition in early September, Pfizer reported third quarter EPS of 60c, which beat consensus estimates of 51c, on revenue of $12.1B, which was also higher than consensus estimates of $11.56B. In Q3 Operational revenue growth in in developed markets was driven primarily by the performance of several key products, including Prevnar 13 in adults, Ibrance and Eliquis -- all products that are early in their life cycles as well as from Lyrica primarily in the U.S., and the inclusion of one month of legacy Hospira U.S. operations. In emerging markets, revenues increased 5% operationally, reflecting continued strong operational growth, primarily from the Innovative Products business. Operational revenue growth was partially offset primarily by the loss of exclusivity and associated generic competition for Celebrex in the U.S., Zyvox in the U.S. and Lyrica in certain developed Europe markets. With its Q3 earnings announcement the company raised its fiscal year 2015 earnings per share view to $2.16-$2.20 from $2.04-$2.10 against a raised revenue view of $47.5B-$48.5B from $46.5B-$47.5B. Commenting on the improved yearly view, the company CFO said "We raised our 2015 financial guidance for reported revenues and adjusted diluted EPS to reflect the strong performance to date of Pfizer-standalone, excluding legacy Hospira operations coupled with an improved business outlook for Pfizer-standalone for the remainder of the year.PFIZER-ALLERGAN DEAL. On November 23, Pfizer and Allergan (AGN) announced that their boards of directors have unanimously approved, and the companies have entered into, a definitive merger agreement under which Pfizer will combine with Allergan. Pfizer at the time said it anticipates the Allergan transaction will deliver more than $2B in operational synergies over the first three years after closing. Pfizer anticipates that the combined company will have a pro forma Adjusted Effective Tax Rate of approximately 17%-18% by the first full year after the closing of the transaction. The transaction is expected to be neutral to Pfizer's Adjusted Diluted EPS in 2017, modestly accretive beginning in calendar year 2018, more than 10% accretive in 2019 with high-teens percentage accretion in 2020. STREET RESEARCH: On December 1, Barclays analyst Geoff Meacham kept an Equal Weight rating on Pfizer after assuming coverage of the name. The analyst maintained a $34 price target for shares.On November 25, SunTrust upgraded Pfizer to Neutral and increased its price target to $37 from $34 on shares. Analyst John Boris said the Allergan deal makes strategic sense, providing much needed growth from earlier life cycle assets with limited therapeutic overlap. PRICE ACTION: Shares of Pfizer are lower by approximately 12% since its last earnings report on October 27. Pfizer shares are trading over 1% lower to $29.97 in afternoon trading ahead of Tuesday morning's earnings.
12:42 EDTHLFHerbalife names John Agwunobi Chief Health and Nutrition Officer
Herbalife announces that John Agwunobi has joined the company as its Chief Health and Nutrition Officer. Most notably, from 2005-2007, he served as the Assistant Secretary of Health for the U.S. Department of Health and Human Services.
10:49 EDTPFEPfizer technical comments before earnings
On the downside, an important support level to watch is at the $28 area. This level has been an important support since early 2013. If the news is a negative surprise, the $28 zone is likely to be tested from current levels. A breakdown below $28 would resolve the range bearishly. Next downside objectives may be at the following support levels: $27.30, $26.42. If the news is a bullish surprise, resistance levels to watch as potential upside objectives would be at $30.95, $31.78, and $32.91. A move above $32.50 would end the current longer-term downtrend.
09:27 EDTHLFOn The Fly: Pre-market Movers
HIGHER: Alere (ALR), up 45.4% after announcing that Abbott (ABT) will acquire the company for $56 per share... Questar (STR), up 20.2% after announcing that Dominion (D) will acquire the company for $25 per share and assumed debt... Mast Therapeutics (MSTX), up 12.2% after the Phase 2a study of AIR001 met its primary endpoint... Twitter (TWTR), up 5.7% after The Information reported that Marc Andreessen and Silver Lake have considered a deal for Twitter... Herbalife (HLF), up 2.2% after the Wall Street Journal reported that probes into Bill Ackman's "pyramid scheme" accusations against Herbalife, as well as Herbalife's own accusations that Ackman sought to manipulate the company's stock, have both failed to uncover enough evidence to support criminal charges. LOWER: Dominion Resources, down 1.7% after reporting quarterly results and that it will acquire Questar... Abbott, down 4.1% after announcing that it will acquire Alere... GoPro (GPRO), down 4.4% after Piper Jaffray cut its price target to $7.50.
09:04 EDTHLFHerbalife moves higher in pre-market
Subscribe for More Information
08:09 EDTPFEOptions expected to be active
Options expected to be active: GOOGL GOOG YHOO UPS KORS UPS BAX RCL CCL PFE AET D STR DWA CMG ABT SYK.
06:58 EDTPFEPortola Pharma licensed right to andexanet alfa to Bristol-Myers and Pfizer
Subscribe for More Information
06:57 EDTPFEBristol-Myers and Pfizer sign collaboration with Portola Pharmaceuticals
Subscribe for More Information
January 31, 2016
20:43 EDTHLFOn The Fly: Top five weekend stock stories
Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Coca-Cola (KO) announced a minority stake in diary and juice company Chi, with plans to take full ownership within three years. 2. Billionaire investor Nelson Peltz is considering taking an activist position in Time Warner (TWX), the New York Post reported. 3. Toyota (TM) could temporarily halt domestic production after an explosion at a key supplier curbed its supply of steel, Reuters said. 4. Investigations into Herbalife (HLF), as well as investigations into Bill Ackman himself, have fizzled and criminal charges look unlikely, the Wall Street Journal revealed. 5. Virtu Financial (VIRT) and Ctrip (CTRP) were discussed positively by Barron's this week, as well as "tech bargains" Autodesk (ADSK), Akamai (AKAM), Western Digital (WDC), SanDisk (SNDK) and Lam Research (LRCX) and attractive banking stocks Citi (C), JPMorgan (JPM), Bank of America (BAC) and Wells Fargo (WFC).
19:24 EDTHLFHerbalife, Ackman probes fail to find criminal evidence, WSJ says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use